3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 1
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Breast Neoplasms
2419
Neoplasms
1838
Carcinoma, Non-Small-Cell Lung
1591
Prostatic Neoplasms
1296
Colorectal Neoplasms
1117
Lung Neoplasms
981
Neoplasm Metastasis
828
Multiple Myeloma
793
Leukemia, Myeloid, Acute
773
Ovarian Neoplasms
673
Pancreatic Neoplasms
667
Melanoma
660
Squamous Cell Carcinoma of Head and Neck
589
Recurrence
563
Carcinoma, Hepatocellular
562
Brain Neoplasms
515
Glioblastoma
505
Stomach Neoplasms
501
Head and Neck Neoplasms
492
Triple Negative Breast Neoplasms
471
Lymphoma
460
Uterine Cervical Neoplasms
444
Carcinoma, Renal Cell
426
Precursor Cell Lymphoblastic Leukemia-Lymphoma
420
Lymphoma, Non-Hodgkin
387
Endometrial Neoplasms
377
Sarcoma
365
Lymphoma, Follicular
357
Urinary Bladder Neoplasms
356
Lymphoma, Large B-Cell, Diffuse
355
Interventions
vistusertib
1
olaparib
1
durvalumab
1
danvatirsen
1
adavosertib
1
Neoadjuvant Therapy
1
Cystectomy
1
AZD4547
1
AZD 6244
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Muscle Invasive Bladder Cancer
×
1 year
×
Clear all
NCT02546661
2025-12-29
BISCAY
AstraZeneca
Phase 1
Active not recruiting
117 enrolled
NCT07202819
2025-10-02
"NAC-MRI"
Assiut University
Phase NA
Recruiting
76 enrolled